# 2022 NRG Oncology Presentation Schedule

**Oral, Quick Pitch Oral, Poster, and Educational Presentations**  
**OCTOBER 23 - 26, 2022**

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Sunday, October 23, 2022</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| GI-Esophagus NRG/RTOG 1010 | **Title:** Patient-reported outcomes (PROs) in NRG Oncology RTOG 1010: phase III trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing (HER2+) esophageal adenocarcinoma (EAC).  
**Presenter:** Lisa A Kachnic, MD  
**Abstract #:** 117  
* GI Highlights session, 10/26/22 at 8:00am CT, Room 007A/B | Location: Room 301  
Session: SS 04 - GI 1 - Esophageal Cancers: The Pros and Cons of Combined Modality Therapy  
Date/Time: Oct 23, 4:45PM-6:00PM  
Duration: 10 minutes  
Oral |
| Lung SWOG/NRG S1914 | **Title:** SWOG/NRG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT vs. SBRT Alone in High Risk, Early-Stage NSCLC (NCT#04214262).  
**Presenter:** Megan E Daly, MD  
**Abstract #:** 2925 | Location: Exhibit Hall 1  
Session: PQA 01 - Poster Q&A 01 - Lung Cancer and DEIH  
Date/Time: Oct 23, 4:45PM-6:00PM  
Poster |

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Monday, October 24, 2022</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| Breast NRG/RTOG 1005 | **Title:** NRG RTOG 1005: A Phase III Trial of Hypo fractionated Whole Breast Irradiation with Concurrent Boost Versus Conventional Whole Breast Irradiation plus Sequential Boost following Lumpectomy for High Risk Early-Stage Breast Cancer.  
**Presenter:** Frank A Vicini, MD  
**Abstract #:** 1 | Location: Stars at Night Ballroom  
Session: Plenary Session  
Date/Time: Oct 24, 1:30 PM  
Duration: 10 Minutes  
Plenary |
| GU-Prostate NRG/RTOG 9202, NRG/RTOG 9408, NRG/RTOG 9413, NRG/RTOG 9910, NRG/RTOG 0126 | **Title:** Prostate cancer risk stratification in NRG Oncology phase III randomized trials using multi-modal deep learning with digital histopathology.  
**Presenter:** Jonathan D Tward, MD  
**Abstract #:** 2 | Location: Stars at Night Ballroom  
Session: Plenary Session  
Date/Time: Oct 24, 1:40 PM  
Duration: 10 Minutes  
Plenary |
| GI-Non-Colorectal NRG/RTOG 1112 | **Title:** NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937).  
**Presenter:** Laura A Dawson, MD  
**Abstract #:** 52345 | Location: Stars at Night Ballroom  
Session: Plenary Session  
Date/Time: Oct 24, 1:50 PM  
Duration: 10 Minutes  
Plenary |
| Head and Neck NRG-HN004 | **Title:** Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004.  
**Presenter:** Loren K Mell, MD  
**Abstract #:** 52495 | Location: Stars at Night Ballroom  
Session: Plenary Session  
Date/Time: Oct 24, 2:00 PM  
Duration: 10 Minutes  
Plenary |
<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Tuesday, October 25, 2022</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| GU-Prostate NRG/RTOG 0534 | **Title:** The influence of pelvic lymph node dissection volumes on clinical outcomes in NRG/RTOG 0534.  
**Presenter:** William A Hall, MD  
**Abstract #:** 158 | **Location:** Room 214  
**Session:** SS 11 - GU 2 - New Insights into Post-Prostatectomy Radiotherapy  
**Date/Time:** Oct 24, 3:20 PM  
**Duration:** 10 minutes  
**Oral** |
| GU-Prostate NRG/RTOG 1115 | **Title:** RTOG/NRG 1115 quality of life of phase III dose escalated radiation therapy (RT) & standard androgen deprivation therapy (ADT) with GnRH agonist vs. dose escalated RT & ADT with GnRH agonist and orteronel (TAK-700) for men with high-risk prostate cancer.  
**Presenter:** Deborah W Bruner, MD  
**Abstract #:** 2477 | **Location:** Exhibit Hall 1  
**Session:** PQA 06 - Poster Q&A 06 - Genitourinary Cancer, Patient Safety, and Nursing  
**Date/Time:** Oct 25, 2:30 PM-3:45 PM  
**Duration:** 10 minutes  
**Poster** |
| GU-Prostate NRG/RTOG 1115 | **Title:** Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with TAK-700 for men with high-risk prostate cancer (NRG Oncology/RTOG 1115).  
**Presenter:** Dror Michaelson, MD  
**Abstract #:** 220 | **Location:** Hemisfair Ballroom C1  
**Session:** SS 22- GU 4 - Improving Outcome for High-Risk Prostate Cancer  
**Date/Time:** Oct 25, 4:10 PM  
**Duration:** 10 minutes  
**Oral** |
| GU-Bladder INTACT SWOG/NRG 1806 | **Title:** INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients.  
**Presenter:** Sameer G Jhavar, MD, PhD  
**Abstract #:** 237 | **Location:** Hemisfair Ballroom C1  
**Session:** SS 25 - GU 5 - Bladder and Kidney Preservation  
**Date/Time:** Oct 25, 5:45 PM  
**Duration:** 7 minutes  
**Oral** |
| Brain NRG-CC001 | **Title:** Evaluating the Utility of EQ5D-5L in Patients with Brain Metastases: Secondary Analysis of NRG-CC001.  
**Presenter:** H Ryan Cherng, MD  
**Abstract #:** 189 | **Location:** Room 007 C/D  
**Session:** SS 17 - PRO 1 - Incorporating the Patient Voice: A Session Focused on PROs and Survivorship  
**Date/Time:** Oct 25, 12:55 PM  
**Duration:** 7 minutes  
**Oral** |

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Wednesday, October 26, 2022</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| Head and Neck NRG/RTOG 0522 | **Title:** A retrospective analysis of NRG/RTOG 0522: low myofibroblast content in the tumor-associated stroma may predict response to epidermal growth factor receptor (EGFR) inhibitors.  
**Presenter:** Yoseful Haque, MD  
**Abstract #:** 2647 | **Location:** Exhibit Hall 1  
**Session:** PQA 09 - Poster Q&A 09 - Head & Neck Cancer and Health Services Research  
**Date/Time:** Oct 26, 10:30 AM-11:45 AM  
**Poster** |
**Presenter:** Thomas J Galloway, MD  
**Abstract #:** 282 | **Location:** Room 214  
**Session:** SS 33 - H&N 3 - Toxicity Mitigation and HPV-Unrelated Head and Neck Cancer - Life Beyond De-Intensification  
**Date/Time:** Oct, 26, 1:00 PM  
**Duration:** 10 minutes  
**Oral** |
<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>The following presentations include NRG data from the NCTN Data Archive or Data Sharing</th>
<th>Time/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sunday, October 23, 2022</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| GU-Prostate NRG/RTOG 0126, NRG/RTOG 0415 | **Title:** Conditional Survival of Patients with Prostate Cancer Undergoing External-Beam Radiotherapy on RTOG 0126 and 0415.  
**Presenter:** Gregory S Alexander, MD  
**Abstract #:** 1003 | **Location:** Room 304  
**Session:** QP 01 - GU 1 - Improving Prostate Cancer Survival  
**Date/Time:** Oct 23, 8:05 AM  
**Duration:** 5 minutes  
**Oral** |
| Lung NRG/RTOG 0617 | **Title:** Explainable Artificial Intelligence for Identification of Dosimetric Predictors of Radiation Toxicity: A Secondary Analysis of RTOG 0617.  
**Presenter:** Colton J Ladbury, MD  
**Abstract #:** 1007 | **Location:** Room 304  
**Session:** QP 02 - DHI 1 - Individualizing Treatment Using AI: Opportunities and Challenges  
**Date/Time:** Oct 23, 4:55 PM  
**Duration:** 5 minutes  
**Oral** |
| Lung NRG Oncology Multi Lung | **Title:** Disparities in Racial and Ethnic Enrollment and Reporting: An Analysis of Reported NRG Radiation Oncology Trials.  
**Presenter:** Colton J Ladbury, MD  
**Abstract #:** 2296 | **Location:** Exhibit Hall  
**Session:** PQA 01 - Poster Q&A 01 - Lung Cancer and DEIH  
**Date/Time:** Oct 23, 4:45 PM-6:00 PM  
**Poster** |
| **Tuesday, October 25, 2022** |                                                                                   |               |
| Lung NRG/RTOG 0617 | **Title:** Explainable Boosting Machine for Choosing Radiation Dose-Volume Constraints on Cardio-Pulmonary Substructures Associated with Overall Survival in the NRG Oncology RTOG 0617 Clinical Trial.  
**Presenter:** Sang Ho Lee, PhD  
**Abstract #:** 178 | **Location:** Room 008  
**Session:** SS 15 - DHI 3 - Leveraging AI to Strengthen Clinical Decision Frameworks  
**Date/Time:** Oct 25, 8:10 AM  
**Duration:** 7 minutes  
**Oral** |
| Lung NRG/RTOG 0617 | **Title:** Left Anterior Descending Coronary Artery Radiation Dose Association with All-Cause Mortality in NRG Oncology Trial RTOG 0617.  
**Presenter:** Elizabeth McKenzie, PhD  
**Abstract #:** 201 | **Location:** Hemisfair Ballroom C1  
**Session:** SS 19 - Lung 2 - Optimizing Thoracic RT Planning and Reducing Treatment Toxicity  
**Date/Time:** Oct 25, 12:45 PM  
**Duration:** 7 minutes  
**Oral** |
| GU-Prostate NRG/RTOG 0126, NRG/RTOG 0415 | **Title:** Toxicity Analysis of Patients with Prostate Cancer Treated with 3D-Conformal Compared to Intensity Modulated Radiotherapy: Secondary Analysis of RTOG 0126 and RTOG 0415.  
**Presenter:** Rebecca F Krc, DO  
**Abstract #:** 2508 | **Location:** Exhibit Hall 1  
**Session:** PQA 06 - Poster Q&A 06 - Genitourinary Cancer, Patient Safety, and Nursing  
**Date/Time:** Oct 25, 2:30 PM-3:45 PM  
**Poster** |